The U.S. Food and Drug Administration (FDA) has approved Cereno Scientific’s investigational drug CS1 in an…
Andrea Lobo
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, including stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Andrea Lobo
Atrial fibrillation or AF — a heart condition marked by an irregular heartbeat — is associated with longer hospital stays,…
When choosing a treatment regimen, people with pulmonary arterial hypertension (PAH) consider the impact on physical limitations and survival…
Treating children with Revatio (sildenafil) reduced pulmonary arterial pressure after surgery for congenital heart disease (CHD), according to a…
The ARRDC3 gene — implicated in inflammation and cell growth — may be a ferroptosis-related biomarker and treatment target in…
Corsair Pharma has secured $23 million in financing to support clinical testing of a skin patch for the…
A joint initiative between a Singapore-based medical technology company and Duke University is aiming to develop and commercialize artificial intelligence,…
Gradient Denervation Technologies has raised €14 million (around $14.9 million) in funding to support the clinical development and testing…
Treatment with treprostinil improved the risk profile in people with inoperable or persistent severe chronic thromboembolic pulmonary hypertension (CTEPH).
Echocardiography, a noninvasive imaging method to examine heart structure and function, can be useful in making a preliminary diagnosis of…
About one-quarter of the pulmonary arterial hypertension (PAH) patients in a small study showed cognitive deficits, typically mild impairments…
Babies born preterm, or before 37 weeks of pregnancy, were shown to have a higher risk of developing pulmonary…